T-Cell Lymphoma

Type: Keyphrase
Name: T-Cell Lymphoma
First reported 11 hours ago - Updated 11 hours ago - 1 reports

Teen won't let cancer slow him down

CANCER hasn't stopped 16-year-old Billy Whittle from going to school and it certainly hasn't stopped him from being the ambassador for this year's Cruise for Cancer.The roaring annual fundraiser, organised by the Rotary Club of Toowoomba City and the ... [Published Queensland Times - 11 hours ago]
First reported Jul 23 2014 - Updated Jul 24 2014 - 2 reports

Belinostat for Relapsed/Refractory Peripheral T-Cell Lymphoma

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms,administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.On July 3, 2014, belinostat ... [Published The ASCO Post - Jul 24 2014]
First reported Jul 14 2014 - Updated Jul 15 2014 - 2 reports

Boost to cancer cell diagnosis

Technology developed in Europe could pave the way for better cancer cell diagnosis.A recent study led by scientists from the Medical University of Vienna (MUV) found that two independent pathologists were only able to agree on around 33% of cancer cell ... [Published Laboratorytalk - Jul 14 2014]
First reported Jul 14 2014 - Updated Jul 14 2014 - 1 reports

Spectrum receives FDA approval for peripheral T-cell lymphoma drug

Spectrum Pharmaceuticals, a biotechnology company, has received accelerated approval from FDA for Beleodaq for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma, or PTCL. ... [Published Individual.com - Jul 14 2014]
First reported Jul 08 2014 - Updated Jul 09 2014 - 2 reports

FDA Approves Drug for Non-Hodgkin Lymphoma

FDA approved Spectrum Pharmaceutical’s Beleodaq (belinostat) for the treatment of patients with peripheral T-cell lymphoma (PTCL), a rare type of non-Hodgkin lymphoma. The action was taken under the agency’s accelerated approval program.Beleodaq works ... [Published PharmTech.com - Jul 09 2014]
First reported Jul 09 2014 - Updated Jul 09 2014 - 1 reports

FDA approves belinostat for peripheral T-cell lymphoma

Belinostat, a histone deacetylase inhibitor, has been approved for treating peripheral T-cell lymphoma, based on the results of the BELIEF study that found an overall response rate of nearly 26%... ... [Published Cardiology News - Jul 09 2014]
First reported Jul 07 2014 - Updated Jul 08 2014 - 2 reports

BioAlliance announces FDA accelerated approval for T-cell lymphoma drug

BioAlliance Pharma SA, a biopharmaceutical company, has announced the accelerated approval from FDA for Topotarget's Beleodaq, for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma, or R/R PTCL. This follows a Priority Review ... [Published Individual.com - Jul 08 2014]
First reported Jul 07 2014 - Updated Jul 07 2014 - 3 reports

Cancer Survivor Runs From Florida to Maine in 68 Days>

Helene Neville won't let four bouts of cancer slow her down.The 53-year-old grandma just finished the third leg of her 10,000-mile run around the perimeter of the lower continental 48 states."I love that you never know what's around the next corner because ... [Published KABC Los Angeles - Jul 07 2014]
First reported Jul 07 2014 - Updated Jul 07 2014 - 3 reports

FDA Grants Spectrum Pharmaceuticals Accelerated Approval of Beleodaq™ for Injection

Spectrum Pharmaceuticals, with a primary focus in Hematology and Oncology, announced today that the U.S. Food and Drug Administration (FDA) has granted Accelerated Approval of Beleodaq™ for the treatment of patients with relapsed or refractory peripheral ... [Published PharmaceuticalProcessing - Jul 07 2014]
First reported Jul 04 2014 - Updated Jul 05 2014 - 2 reports

FDA accelerates approval of Beladoaq to treat peripheral T-cell lymphoma

Beleodaq (belinostat) just received FDA approval for the for the treatment peripheral T-cell lymphoma (PTCL), a rare and fast-growing type of non-Hodgkin lymphoma (NHL). The drug works by stopping enzymes that can turn T-cells (a form of immune cell) ... [Published Examiner.com - Jul 05 2014]
First reported Jul 03 2014 - Updated Jul 04 2014 - 21 reports

FDA approves Spectrum’s Beleodaq for PTCL

Under its accelerated approval program, the US Food and Drug Administration late yesterday cleared Spectrum Pharmaceuticals’ (Nasdaq: SPPI)Beleodaq (belinostat) for the treatment of patients with peripheral T-cell lymphoma (PTCL), a rare and fast-growing ... [Published Pharma Letter - Jul 04 2014]
First reported Jul 04 2014 - Updated Jul 04 2014 - 2 reports

Spectrum Puts Its Eggs In One Basket: Folotyn, Beleodaq To Share Confirmatory Trial

With Spectrum’s Beleodaq’s accelerated approval for peripheral T-cell lymphoma, FDA rolls Folotyn accelerated approval requirement into one post-marketing trial that will provide answers on both drugs – including which is better against standard of c ... [Published Health News Daily - Jul 04 2014]

Quotes

"Giving back to others who have helped me is very good."
...choice to advance the development of darinaparsin on a global basis," said Jonathan Lewis, M D , Ph D , Chief Executive Officer of ZIOPHARM. "Through a collaboration that began in 2011, Solasia has built a meaningful scientific and clinical understanding of darinaparsin, providing a strong foundation for realizing its long-term clinical value. Further, by expanding this agreement to all global territories, there exists now an additional strong incentive for Solasia to rapidly and strategically develop this potentially important product candidate in areas of unmet medical need in oncology."
Infringement of U S Patent Nos. 6,028,071 ( "Purified Compositions of 10-propargyl-10-deazaaminopterin and Methods of Using Same in the Treatment of Tumors" issued February 22, 2000), 7,622,470 ("Treatment of T-cell Lymphoma Using 10-porpargyl-10-deazaaminopterin," issued November 24, 2009), and 8,200,078...
Acknowledging the distance to go between this discovery and finding a cure for good, Dr Søgaard said: "There is still a long way to go and many obstacles to overcome before we can start talking about a cure against HIV. We have now shown that we can activate a hibernating virus with romidepsin and that the activated virus moves into the bloodstream in large amounts.”"

More Content

All (110) | News (103) | Reports (0) | Blogs (5) | Audio/Video (0) | Fact Sheets (0) | Press Releases (1)
sort by: Date | Relevance
Teen won't let cancer slow him down [Published Queensland Times - 11 hours ago]
ZIOPHARM Oncology and Solasia Pharma Announce G... [Published GlobeNewswire - 17 hours ago]
Fully Human Antagonistic Antibodies against CCR... [Published Plosone.org - 18 hours ago]
New products for pharmacists 08-10-2014 [Published Drugtopics.com - 18 hours ago]
Court Report -- Part II - July 2014 #2 [Published JD Supra - Jul 30 2014]
Local researchers working to cure cancer [Published Lubbock Online - Jul 29 2014]
Belinostat for Relapsed/Refractory Peripheral T... [Published The ASCO Post - Jul 24 2014]
FDA Approves Belinostat for Relapsed or Refract... [Published The ASCO Post - Jul 23 2014]
A Patient's Guide to Second Opinions [Published US News & World Report - Jul 23 2014]
Celgene's cancer drug Isodax could re-activate ... [Published Pharma Letter - Jul 23 2014]
New Study: Anti-Cancer Drug For HIV [Published Your Story - Jul 22 2014]
Celgene drug can drive HIV out of hiding -study [Published Reuters - Jul 22 2014]
Progress Report [Published Advance for NPs and PAs - Jul 19 2014]
Diseases, symptoms, genes, and proteins linked ... [Published Medical Xpress - Jul 18 2014]
Surgery for Primary Central Nervous System Lymp... [Published Cancernetwork.com - Jul 18 2014]
Allos Therapeutics Sues Dr. Reddy’s Over Propos... [Published FDA News - Jul 17 2014]
FDA Updates for Health Professionals - 07/16/14 [Published Food Consumer - Jul 16 2014]
Seattle Genetics Nearing Key Test for Investor ... [Published TheStreet.com - Jul 16 2014]
Seattle Genetics Nearing Key Test for Investor ... [Published The Street Latest - Jul 16 2014]
BioAlliance Pharma: FDA approval of Beleodaq? b... [Published Pharmacy Choice - Jul 16 2014]
Cutaneous intravascular natural killer-cell lym... [Published American Journal of Clinical Pathology - Jul 16 2014]
New technology developed to diagnose cancer cells [Published Medical News Today - Jul 15 2014]
What You Missed From The FDA Last Week July 7-1... [Published Pharmaceutical Online - Jul 14 2014]
Spectrum receives FDA approval for peripheral T... [Published Individual.com - Jul 14 2014]
Boost to cancer cell diagnosis [Published Laboratorytalk - Jul 14 2014]
New technology developed to diagnose cancer cells [Published Health Canal - Jul 14 2014]
ProStrakan Acquires Archimedes Pharma for $394M [Published Genetic Engineering News - Jul 11 2014]
FDA Approves Drug for Non-Hodgkin Lymphoma [Published PharmTech.com - Jul 09 2014]
FOLOTYN SOLUTION FOR INFUSION 20 MG/ML [Published Medical Grapevine - Jul 09 2014]
FDA Approves Beleodaq (belinostat) [Published Individual.com - Jul 09 2014]
1 2 3 4
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Weekly Roundup 7.4.14 [Published Eye on FDA - Jul 04 2014]
Happy Independence Day for America.  This week also so Canada Day.  So while a week where work productivity may have dipped, enjoyment factors probably drove up – at least in North America.  The season is marked by hot, humid days and stormy nights, ...
BioAlliance's lymphoma drug Beleodaq gets accel... [Published PBR - News - Jul 04 2014]
France-based BioAlliance Pharma has received topotarget accelerated approval from the US Food and Drug Administration (FDA) for Beleodaq to treat patients with relapsed or refractory peripheral T-cell lymphoma (R/R PTCL). ...
BioAlliance Pharma: FDA approval of Beleodaq™ (... [Published Business Wire Health News - Jul 03 2014]
PARIS--(BUSINESS WIRE)--Regulatory News: BioAlliance Pharma SA (Paris:BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Topotarget ...
Beleodaq Approved for Aggressive non-Hodgkin Ly... [Published Yahoo! Health News - Jul 03 2014]
THURSDAY, July 3, 2014 (HealthDay News) -- Beleodaq (belinostat) has been approved by the U.S. Food and Drug Administration to treat peripheral T-Cell lymphoma (PTCL), a rare and aggressive form of non-Hodgkin lymphoma (cancer of the lymph nodes).... ...
Beleodaq OK'd for Rare Form of NHL [Published MedPageToday.com - medical news plus CME for ph ... - Jul 03 2014]
WASHINGTON (MedPage Today) -- The FDA has approved the histone deacetylase inhibitor belinostat for treatment of peripheral T-cell lymphoma, an uncommon but aggressive form of non-Hodgkin's lymphoma (NHL). ...
1

Press Releases

sort by: Date | Relevance
Topotarget confirms receipt of acceptance-to-fi... [Published GlobeNewswire: Advertising News - Mar 26 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.